Dr. Shang-Chiung Chen obtained his Ph.D. degree in the department of Molecular Pharmacology and Cancer Therapeutics, Roswell Park Cancer Institute Graduate Division, SUNY at Buffalo. Currently, he is a post-doctoral fellow in the Center for Protein Therapeutics, and he is investigating the determinants of the target-mediated disposition of anti-CEA antibodies.